<DOC>
	<DOCNO>NCT02850965</DOCNO>
	<brief_summary>To evaluate efficacy compare efficacy safety BI 695501 versus Humira patient moderate severe chronic plaque psoriasis .</brief_summary>
	<brief_title>Efficacy , Safety Immunogenicity BI 695501 Versus Humira® Patients With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion criterion : Males female age &gt; =18 = &lt; 80 year diagnosis moderate severe chronic plaque psoriasis ( without psoriatic arthritis ) least 6 month first administration study drug ( selfreported diagnosis confirm investigator acceptable ) , stable last 2 month change morphology significant flare Screening Baseline ( Randomization ) : involve BSA &gt; = 10 % PASI score &gt; = 12 sPGA score &gt; = 3 . Participants reproductive potential ( childbearing potential ) must willing able use highly effective method birth control per International Council Harmonization ( ICH ) M3 ( R2 ) result low failure rate le 1 % per year use consistently correctly trial 6 month follow completion discontinuation trial medication . Signed date write informed consent accordance Good Clinical Practice ( GCP ) local legislation prior admission trial . Patients candidate systemic therapy . Exclusion criterion : Active ongoing inflammatory disease psoriasis might confound trial evaluation accord investigator ` judgment . Previous treatment 1 biological agent , adalimumab adalimumab biosimilar . No prior biologic exposure within last 6 month screen . Patients significant disease psoriasis and/or significant uncontrolled disease ( , limit , nervous system , renal , hepatic , endocrine , hematological , autoimmune gastrointestinal disorder ) . Major surgery perform within 12 week prior randomization plan within 6 month screen , e.g. , total hip replacement . Any document active suspected malignancy history malignancy within 5 year prior screen , except appropriately treat basal cell carcinoma skin situ carcinoma uterine cervix . Patients must wish continue intake restricted medication drug consider likely interfere safe conduct trial . Currently enrol another investigational device drug study , less 30 day since end another investigational device drug study ( ) , receive investigational treatment ( ) . Chronic alcohol drug abuse Women pregnant , nursing , plan become pregnant course study within period least 6 month follow completion discontinuation trial . Forms psoriasis ( e.g. , pustular , erythrodermic guttate ) chronic plaque psoriasis . Druginduced psoriasis ( i.e. , new onset current exacerbation e.g. , beta blocker lithium ) . Primary secondary immunodeficiency ( history , currently active ) , include know history HIV infection positive HIV test screening ( per investigator discretion mandate local authority ) . Known chronic relevant acute tuberculosis ; evidence active tuberculosis . Known clinically significant coronary artery disease , significant cardiac arrhythmia , moderate severe congestive heart failure ( New York Heart Association Classes III IV ) interstitial lung disease observe chest Xray . History severe allergic reaction , anaphylactic reaction , hypersensitivity previously use biological drug excipients . Positive serology hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Receipt live/attenuated vaccine within 12 week prior Screening Visit ; patient expect receive live/attenuated virus bacterial vaccination trial 3 month last dose trial drug . Any treatment ( include biologic therapy ) , opinion investigator , may place patient unacceptable risk trial . Known active infection kind ( exclude fungal infection nail bed ) , major episode infection require hospitalization treatment intravenous ( i.v . ) anti infectives within 4 week Screening Visit Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 time upper limit normal ( ULN ) Screening . Hemoglobin &lt; 8.0 g/dL Screening . Platelets &lt; 100,000/µL Screening . Leukocyte count &lt; 4000/µL Screening . Creatinine clearance &lt; 60 mL/min/1.73 m2 Screening . Patients history clinically significant adverse reaction murine chimeric protein , natural rubber latex , include serious allergic reaction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>